Boeing Co
Change company Symbol lookup
Select an option...
BA Boeing Co
GILD Gilead Sciences Inc
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp

Industrials : Aerospace & Defense | Large Cap Value
Company profile

The Boeing Company is an aerospace firm. The Company operates in four segments: Commercial Airplanes (BCA); Defense, Space & Security (BDS); Global Services (BGS), and Boeing Capital (BCC). BCA segment develops, produces and markets commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. BDS segment is engaged in the research, development, production and modification of manned and unmanned military aircraft and weapons systems for strike, surveillance and mobility. BGS segment provides services to commercial and defense customers worldwide. BCC's segment portfolio consists of equipment under operating leases, finance leases, notes and other receivables and assets held for sale.

Closing Price
Day's Change
0.49 (0.27%)
B/A Size
Day's High
Day's Low

10-day average volume:

UPDATE: Inovio's stock surges to extend rally to 20-year high, while Stifel says price is now 'less palatable'

12:21 pm ET June 26, 2020 (MarketWatch)

Shares of Inovio Pharmaceuticals Inc. (INO) rallied 7.5% in premarket trading Friday, to extend their recent rocket ride to a 20-year high, even as biotechnology company was downgraded at Stifel Nicolaus on valuation concerns. The stock has run up 119% amid a four-day win streak to close Thursday at the highest price since September 2000, and has soared more than 9-fold (up 847%) year to date--the S&P 500 has lost 4.6% this year--as the company has a COVID-19 vaccine candidate ( in Phase 1 trials. Stifel analyst Stephan Willey raised his stock price target to $24 from $19, but cut his rating to hold after being at buy for at least the past 3 1/2 years, saying the risk-versus-reward investment scenario "seems less palatable" at current prices. " While acknowledging peer COVID-19 vaccine company valuations would suggest we're potentially leaving significant upside on the table should promising immunogenicity data (i.e. robust neutralizing antibody responses) and a large government-written check subsequently materialize, we also believe any potential downside risk in the absence of the aforementioned events occurring is equally-significant," Willey wrote in a note to clients.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

June 26, 2020 12:21 ET (16:21 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.